The short synthetic interfering RNA duplexes (siRNAs) can selectively suppress gene expression in somatic mammalian cells without nonselective toxic effects of double-stranded RNA (dsRNA). However, a selective in vivo delivery of siRNA transfer has not been reported in kidney. Here, we investigated whether injection of synthetic siRNAs via renal artery followed by electroporation could be effective and therapeutic in silencing specific gene in glomerulus. We investigated the effect of siRNA in rat cultured mesangial cells (MCs) and showed that siRNA sequence-specific suppression of transgene expression was over a 1000-fold more potent than that by antisense oligodeoxynucleotide (ASODN). Transfection of siRNA targeting luciferase into rat kidneys significantly inhibited expression of a cotransfected luciferase expression vector in vivo. The delivery of siRNA targeting enhanced green fluorescent protein (EGFP) in the transgenic 'green' rat reduced endogenous EGFP expression, mainly in glomerular MCs. Furthermore, RNAi targeting against TGF-b1 significantly suppressed TGF-b1 mRNA and protein expression, thereby ameliorated the progression of matrix expansion in experimental glomerulonephritis. In addition, vector-based RNAi also inhibited TGF-b1 expression in vitro and in vivo. In conclusion, siRNA-directed TGFb1 silencing may be of therapeutic value in the prevention and treatment of fibrotic diseases. Gene Therapy (2005) 12, 965-973.
Introduction
RNA interference (RNAi), which is initiated by the introduction of double-stranded RNA (dsRNA) into the cell, leads to the sequence-specific destruction of endogenous RNA.
1,2 RNAi-induced gene-specific silencing has been proven successful in organisms such as Caenorhabditis elegans and plants. However, the application of long dsRNA in vertebrates is limited because it induces a generalized suppression of protein synthesis and cell death by activating the interferon pathway. 3 Tuschl et al 4 made a crucial breakthrough that short synthetic interfering RNA duplexes (siRNAs) can selectively silence the expression of complementary genes in somatic mammalian cells without the nonselective toxic effects of long dsRNAs. These observations in mammals not only produced the next generation of genetic research, but also allowed the development of new therapies. An important step in realizing the potential of RNAi as a therapeutic tool is determining if this mechanism can be triggered in vivo. Recently, we developed an electroporation-mediated gene transfer system targeting the kidney: DNA is injected via the renal artery, and is followed by electric pulses with tweezers-type electrodes. 5 This system allows us to deliver DNA mainly to the glomeruli, a region central to the inflammatory response in the initiation and progression of various kidney diseases. Therefore, we investigated whether electroporation-mediated introduction of synthetic siRNA could be effective in silencing transgene and endogenous gene expression in glomeruli. Furthermore, to prove the therapeutic application of transfected siRNA in an animal disease model, we targeted TGF-b1, a potent cytokine which plays an important role in the fibrogenic phase of various diseases, including glomerulonephritis. 6 Also, we examined the efficacy of a siRNAproducing DNA-based vector system. Here, we showed that electroporation-mediated siRNA transfer inhibited glomerular gene expression, and that RNAi targeting TGF-b1 could be therapeutic in renal disease.
Results

Effect of synthetic siRNA in vitro
We investigated whether siRNA is effective in rat mesangial cells (MCs) and compared its effect with that of antisense oligodeoxynucleotides (ASODNs). In MCs treated with siRNA targeting luciferase GL-3 (siGL-3), 4 expression of Photinus pyralis luciferase was inhibited 50-95% in a dose-dependent fashion (0.01-50 nM), when compared with scrambled siRNA (siSCR) (Figure 1a ). In contrast, ASODN targeting GL-3 (ASGL-3) 7 inhibited luciferase activities by only 30 and 40% at the concentration of 50 and 100 nM, respectively. We observed no significant suppression in MCs transfected with siRNA targeting luciferase GL-2 , a variant of luciferase GL-3 (siGL-2). 4 Expression of Renilla reniformis luciferase was also unaffected by siGL-3. These observations suggest that inhibition by siRNA is specific to the target gene and is over a 1000 times more effective than ASODN.
Effect of synthetic siRNA in vivo
We then tested whether electroporation-mediated siRNA transfection could silence gene expression effectively in kidney in vivo. For in vivo studies, luciferse plasmid combinations (pGL-3 and pRL-TK) were co-transfected with siGL-3 or siGL-2 by electroporation into the kidney. In rats receiving siGL-3, glomerular expression of P. pyralis luciferase was inhibited by about 70%, when compared with siSCR-treated rats (Figure 1b) . Treatment with siGL-2 did not affect P. pyralis luciferase activity. These results demonstrate that siRNA can be delivered to the glomeruli using electroporation method and, subsequently, gene expression is inhibited in a sequence-specific manner.
To identify the cellular localization of siRNA delivered to the kidney, we employed siRNA targeting enhanced Figure 1 siRNA-mediated silencing of luciferase in vitro and in vivo. siRNA-mediated silencing of luciferase in rat primary MCs (a). The average of three independent experiments is shown; error bars indicate standard deviation. *Po0.001 compared with siGL-2. **Po0.01 compared with siGL-2 or SGL-3. siRNA-mediated silencing of luciferase in rat glomeruli (b). The average of three independent experiments is shown (n ¼ 4); error bars indicate standard deviation. *Po0.01 compared with siGL-2. Figure 2 siRNA-mediated silencing of EGFP expression in the glomerular cells. Representative fluorescence micrographs of glomeruli in the siEGFPtransfected (right) and contralateral (left) kidney, which were taken 7 days after transfection (a, upper). Sections were stained with Texas red-labeled OX-7 antibody, a marker of MCs (a, middle), and merged photos are shown (a, lower). Original magnifications are Â 400. Representative fluorescence micrographs of siEGFP-transfected gromeruli at various time point (b, upper) and ratios of EGFP-knocked down MCs were presented (b, lower). Total RNA extracted from transfected glomeruli was subjected to Northern blot analysis to detect siEGFP using 5 0 end-labeled oligodeoxynucleotide probe (c). Synthetic siEGFP (0.2 ng) was used as a positive control and a size-marker (M).
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Y Takabatake et al green fluorescent protein (EGFP) (siEGFP), and transferred siEGFP to the kidney of EGFP transgenic rats. 8 At 7 days after transfection, EGFP expression was diminished substantially in almost all of the glomeruli (495%), while it was unchanged in the tubules (Figure 2a ). This inhibition seemed nearly complete in MCs stained red with Texas red-labeled OX-7 antibody (Figure 2a , lower panel), whereas in other glomerular cells, endothelial and epithelial cells, no inhibition of EGFP expression was observed. These results demonstrate that siRNA effectively inhibits the expression of a transgene expressed from the genome, at least in glomerular MCs. The reduction of mesangial EGFP expression was observed for up to 2 weeks, but recovered completely 3 weeks after transfection (Figure 2b, upper panel) . Quantitative data were also summarized (Figure 2b, lower panel) . Moreover, to examine the fate of transfected siRNA in glomeruli, total glomerular RNA was subjected to Northern blot analysis detecting the amount of remained siEGFP in glomeruli (Figure 2c ). In consistent with the morphological effect, transfected siRNA was degraded gradually and signal was almost undetectable three weeks after transfection.
Effect of synthetic siRNA targeting TGF-b1
To investigate the therapeutic potential of siRNA, we targeted TGF-b1. First, we determined the optimal siRNA sequence to target TGF-b1 using cultured rat MCs. Three different TGF-b1-specific siRNAs (siTGFA, siTGFB and siTGFC) were synthesized. Northern blot analysis demonstrated siSCR or siTGFC transfection did not affect the FCS-induced increase in TGF-b1 mRNA levels ( Figure 3a) . In contrast, TGF-b1 mRNA levels in MCs transfected with siTGFA, siTGFB decreased to 0.40-and 0.36-fold respectively, compared to siSCR-transfected cells. As the treatment with siTGFB reduced the levels of TGF-b1 mRNA expression most effectively, we employed siTGFB for in vivo experiments.
Next, we tested whether electroporation-mediated delivery of synthetic siTGFB into MCs in vivo could suppress glomerular TGF-b1 expression using the antiThy-1 model of glomerulonephritis, in which TGF-b1 is upregulated in the glomerular MCs. At 24 h after injection of mAb 1-22-3, 50 mg of siTGFB was transfected into the left kidney. Northern blot analysis showed that treatment with siTGFB reduced glomerular TGF-b1 mRNA expression 0.42-fold, as compared to the contralateral right kidney of siTGFB-treated rats or siSCRtransfected kidney (ratios of TGF-b1 signal to GAPDH signal) (Figure 3b ). Western blot analysis demonstrated that siTGFB significantly reduced glomerular TGF-b1 protein expression when compared with the contralateral right kidney (Figure 3c) . No difference in TGF-b1 protein expression was observed between siSCR-transfected left kidneys and contralateral right kidneys. Immunohistochemical examination also showed that TGF-b1 induction was significantly reduced in the siTGFB-treated kidney compared to contralateral nephritic kidney (Figure 4a-e) .
To determine the effect on pathological changes in nephritic kidneys, histological analysis was performed using PAS staining. PAS staining showed that siTGFB transfection reduced extracellular matrix (ECM) accumulation (Figure 4f , h) compared with the contralateral right kidneys of siTGFB-treated rat (Figure 4g , i). We observed strong SMaA expression in the glomeruli of contralateral right kidneys (Figure 4k ). However, immunostaining of SMaA was weak in siTGFB-treated kidneys ( Figure 4j ). Computerized image analysis shows that SMaA expression was significantly suppressed in siTGFB-treated nephritic kidneys compared with contralateral or siSCR-treated kidneys (Figure 4l ). To overcome the shortcomings of chemically synthesized siRNA, several groups have developed DNA-vectormediated mechanism to express substrates that can be converted into siRNA in vitro. In this study, we used the pSilencer 2.0-U6 siRNA expression vector, featuring the human U6 RNA pol III promoter, and constructed pSU6TGFB to encode small hairpin RNA (shRNA) targeting the same sequence as siTGFB and tested its efficacy ( Figure 5a ). By transferring this expression vector into cultured MCs or rat kidney, we verified the transcripts in vitro and in vivo by Northern blot analysis ( Figure 5b ). shRNA, an intermediate in this system, was not detected, probably due to immediate processing by Dicer-like nuclease.
First, we examined shRNA-mediated silencing of TGF-b1 mRNA expression in rat MCs. After transfecting pSU6TGFB or pSU6SCR, TGF-b1 mRNA levels in cultured MCs were estimated by Northern blot analysis ( Figure 5c ). Densitometric analysis showed pSU6TGFB significantly reduced the FCS-induced increase of TGFb1 mRNA levels compared with pSU6SCR-treatment or untreatment. Next, we checked shRNA-mediated silencing of TGF-b1 expression in glomeruli of the anti-Thy-1 nephritis model. TGF-b1 expression of isolated glomeruli was estimated using Northern blot analysis (Figure 5d ) and Western blot analysis (Figure 5e ). pSU6TGFB efficiently inhibited mRNA and protein expression of TGF-b1 in vivo when compared with pSU6SCR. According to these observations, pSU6TGFB ameliorated the pathological changes of the nephritic kidney as efficiently as siTGFB (data not shown).
Discussion
We first demonstrated in this study that siRNA successfully inhibited exogenous and endogenous gene expression in kidney using an electroporation method, thereby validating the potential of siRNA as a therapeutic tool. Exploring RNAi for renal disease Y Takabatake et al
In this study, we showed a selective in vivo delivery of siRNA into kidney. Several researchers tried the in vivo delivery of siRNA in a variety of organs. Using a hydrodynamic-based delivery technique, several groups have demonstrated sequence-specific silencing mainly in liver either by siRNA or by siRNA expression vectors.
9,10
Virus-vector-mediated RNAi in vivo has also been described using recombinant adenovirus 11 and baculovirus. 12 Successful application of RNAi for gene therapy depends on the effective delivery of RNA molecules exclusively to their intended site of action. To our knowledge, however, kidney-targeted siRNA transfer has not been reported. Recently, we developed a new gene transfer system by electroporation in vivo, involving DNA injection via the renal artery followed by electric pulses with tweezers-type electrodes. 5 This technique allows us to deliver DNA mainly to the glomeruli, a region central to the inflammatory response in the initiation and progression of various kidney diseases.
Here, we verified the delivery of synthetic siRNA into rat kidneys by electroporation-mediated gene transfer. Dual luciferase assays showed that siRNA targeting against luciferase decreased the level of glomerular P. pyralis luciferase expression up to 30%, compared with scrambled siRNA-transfected rats. We did not observe the dose-dependency of siGL-3 in vivo (5-50 mg). The observation from our in vitro experiment suggests that less amount of siRNA (o5 mg) might be Figure 5 shRNA-mediated silencing of TGF-b1 expression. Schematic drawing of the construction of pSU6TGFB (a). Two oligodeoxynucleotides containing sense and antisense 21-nt sequences of siTGFB, a 9-nt loop sequence, and a transcription termination signal of six thymidines were annealed and inserted downstream of the U6 promoter. Identification of transcripts expressed from pSU6TGFB in cultured MCs (left) and glomeruli (right) (b). Transcripts expressed from pSU6TGFB (lane 1) or pSU6SCR (lane 2) in rat MCs or glomeruli were probed with either 32 P-labeled sense (S) or antisense (AS) 19-nt oligonucleotide. Synthetic siTGFB (0.2 ng) was used as a size-marker (M). shRNA-mediated silencing of TGF-b1 mRNA expression in rat MCs (c). After transfecting pSU6TGFB or pSU6SCR, TGF-b1 (upper) and GAPDH (lower) mRNA levels in MCs were estimated by Northern blot analysis. Densitometric analysis was performed for three independent experiments. The band density expressed as the mean+s.d. is illustrated (*Po0.01 compared with pSU6SCR). shRNA-mediated silencing of TGF-b1 expression in vivo (d, e). TGF-b1 expression of isolated glomeruli was estimated using Northern blot analysis (d) and Western blot analysis (e). Untransfected contralateral (DC) and normal (N) kidney were also represented. The band density expressed as the mean+s.d. is illustrated (*Po0.01 compared with pSU6SCR and contralateral kidney).
Exploring RNAi for renal disease Y Takabatake et al effective in in vivo gene suppression. We observed no significant inhibition in rats injected with the control siRNA against luciferase GL-2, a variant of luciferase GL-3, suggesting that the inhibition of siRNA was specific to the target gene. In addition, we transfected siRNA targeting EGFP to EGFP-transgenic rats to investigate whether siRNA could be effective in silencing transgene expressed from the genome and to identify its precise site of action in the kidney. At 7 days after transfection, EGFP expression was diminished substantially in almost all of glomeruli, while it remained unchanged in the tubules. This inhibition seemed nearly complete in MCs, whereas no inhibition was observed in other glomerular cells, endothelial and epithelial cells. As a similar transduction pattern occurred when FITC-conjugated ODN was transfected by electroporation, 5 this observation may result from the differences in transfection efficiency between glomerular cell types rather than from the nature of siRNA itself. These results demonstrate that siRNA is effective in inhibiting the expression of a transgene expressed from the genome, at least in a majority of MCs.
In order to prove the therapeutic application of transfected siRNA in an animal disease model, we selected TGF-b1 as the target gene. TGF-b1 is a profibrotic cytokine that plays a pivotal role in fibrosis. 6 We showed that siRNA targeting against TGF-b1 could be therapeutic in anti-Thy-1 nephritis, in which TGF-b1 is upregulated in the glomerulus. 13 In addition to the kidney, inhibition of TGF-b1 activity has been successfully demonstrated in several organs, for example, lung, skin, brain, and arterial wall. 6 In each case, blocking the activity of TGF-b1 dramatically decreased the excessive deposition of ECM, but did not interfere with normal healing of tissue repair. Our observation in this study is applicable to other conditions with TGF-b1 involvement, and the use of siRNA for TGF-b1 may be suitable for the treatment of fibrotic diseases.
In the present study, we demonstrated shRNA expression vector suppressed the target gene expression as efficiently as synthetic siRNAs in vitro and in vivo. A major concern about RNAi is the nonspecific effect, which may be induced by siRNA or shRNA, especially, the interferon responses. Recently, some synthetic siRNAs or shRNA expression vectors were reported to induce interferon responses. 14, 15 This is of critical importance in exploring RNAi for clinical application. However, we did not observe the increase of apoptotic cells nor induction of nonspecific gene inhibition in siRNA-or shRNA-treated MCs in vitro or in vivo glomeruli in vivo. Another concern in applying RNA to gene therapy is the longevity of silencing target gene expression in vivo. It is reported that gene silencing by synthetic siRNAs is transient:
4 levels of target protein in siRNA-treated cells recover 5 or 7 days after transfection, probably due to dilution accompanied with cell division and the nonrenewable nature of siRNAs in mammals. In our study a single transfection of siRNA for EGFP (siEGFP) or its expression vector (data not shown) into kidney resulted in the reduction of mesangial EGFP expression for up to 2 weeks. Of interest is transfection of siEGFP or its expression vector into the anterior tibial muscle by electroporation silenced EGFP expression unexpectedly for more than 90 days (data not shown). These data suggest that the longevity of RNAi may be dependent on the resistance to nuclease attack in individual cells. Therefore, we examined the expression of eri-1, which was recently reported to be a kind of 'siRNase'. 16 The expression of eri-1 was higher in brain and kidney than in muscle (data not shown), which may explain the difference in the duration of silencing. We also showed that the amount of siRNAs derived from its expression vectors as detected by Northern analysis was rather small, especially in vivo (Figure 5b) . Considering the high efficacy of synthetic siRNAs transfection in vitro (480% in MCs) and in vivo (nearly all glomeruli were transfected with siRNA, compared to 75% at the most with DNA vector 5 ), synthetic siRNAs still have some advantages over plasmid-based gene silencing, even in the practical application at present.
In conclusion, siRNA transfer into the renal artery followed by electroporation was effective and siRNAdirected TGF-b1 silencing may be of therapeutic value in the prevention and treatment of fibrotic diseases.
Materials and methods
Cell culture
Rat MCs were isolated and cultured as described previously 17 and were maintained in RPMI 1640 (SIG-MA, St Louis, MO, USA) containing 20% fetal bovine serum (FBS) equilibrated with 5% CO 2 -95% air at 371C. MCs at passage 6-12 were used for in vitro transfection.
Animal studies
The transgenic 'green' rat line, Rat SD TgN (act-EGFP) Osb4, 8 and 6-week-old male Sprague-Dawley (SD) rats, weighing approximately 150 g, were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Anti-Thy-1 glomerulonephritis was induced by a single injection of 700 mg of monoclonal antibody (mAb) 1-22-3. 18 In all animal experiments, rats were anesthetized by intraperitoneal injection of pentobarbital (50 mg/kg) and handled in a humane fashion in accordance with the guidelines of the Animal Committee of Osaka University.
Preparations of siRNA and ASODNs siRNAs (21 nucleotides long) were designed to target luciferase GL-2 (siGL-2), (ASGL-3, SGL-3, respectively) were synthesized and purchased from Bex (Tokyo, Japan).
Exploring
siRNA-mediated inhibition of luciferase activity in vitro and in vivo
To assess the silencing effect of siRNA in the kidney, co-transfection assays were performed in vitro and in vivo. First, reporter plasmids were co-transfected with synthetic siRNAs or ASODN into rat primary MCs by Lipofectamine 2000 reagent (Invitrogen Corp., Carsbad, CA, USA). Reporter plasmid combinations of 1 mg of pGL-3 (Promega, Madison, WI, USA), containing the P. pyralis luciferase gene and 0.1 mg of pRL-TK (Promega) containing the R. reniformis luciferase gene (a quantitative control), were co-transfected into subconfluent rat MCs in 6 cm dishes along with 0.001-50 nM of siGL-3, 10-100 nM of ASGL-3, or 20 nM of siGL-2, an siRNA targeting against a variant of P. pyralis luciferase gene. Scrambled siRNA (siSCR) or sense ODN (SGL-3) at equivalent concentrations was used as a control for siGL-3 or ASGL-3, respectively. At 24 h after transfection, we examined the effect of siRNA by dual luciferase assay (Promega). In all cases, the ratios of P. pyralis luciferase (Pp-luc) to R. reniformis luciferase (Rr-luc) activities were normalized by those observed in equivalent amount of siSCR or SGL-3 treated MCs to compensate for differences in transfection efficiencies. For in vivo studies, reporter plasmid combinations (200 mg of pGL-3 and 10 mg of pRL-TK) were cotransfected with 5-50 mg of siGL-3 or 50 mg of siGL-2 by electroporation into the kidney as previously described (n ¼ 4 in each group).
5 At 4 days after transfection, rat glomeruli were collected by a graded sieving technique 20 and prepared homogenates were screened for the activity of target P. pyralis luciferase and control R. reniformis luciferase by dual luciferase assay.
siRNA-mediated inhibition of EGFP expression in glomeruli
To identify transfected cells in the kidney, we transfected 50 mg of siEGFP to the kidney of EGFP-transgenic rats via the renal artery, followed by electroporation (n ¼ 4). At 7 days after transfection, kidneys were examined by immunofluorescence. Kidneys were fixed in ice-cold neutral-buffered 4% paraformaldehyde (PFA) solution and embedded in O.C.T. compound (Tissue-Tek, Sakura Finetek USA, Inc., Torrance, CA, USA). The cryostat sections (4 mm thick) were stained with the monoclonal antibody OX-7, a specific marker for MCs (a kind gift from Dr Ken-ichi Isobe and Professor Seichi Matsuo, Nagoya University, Nagoya, Japan). After blocking in 5% normal horse serum in PBS, sections were incubated with OX-7 (1:200) for 1 h at room temperature, followed by Texas red-conjugated anti-mouse IgG (1:200) (Vector Laboratories, Inc., Burlingame, CA, USA) for 30 min at room temperature. The green fluorescence of EGFP and red fluorescence were photographed on the same film by double exposure. Contralateral kidneys were used as normal controls. To examine the reduction of EGFP expression quantitatively, we selected 20 glomeruli from each sample at various time point and the red staining area on merged image (showing the EGFP-knocked down MS area) relative to that on nonmerged image (showing total MS area) was calculated automatically as a percentage using Mac SCOPE program. Moreover, to elucidate the fate of transfected siRNA, Northern blot analysis detecting siEGFP was performed using total RNA extracted from siEGFP-transfected glomeruli. 5 0 end-labeled oligodeoxynucleotide (5 0 -GGCTACGTC CAGGAGCGCA-3 0 ) that is complementary to antisense strand of siEGFP was used as a probe. Synthetic siEGFP (0.2 ng) was used as a positive control and a size-marker.
siRNA-mediated inhibition of TGF-b1 in vitro and in vivo
To target TGF-b1, we examined the optimal sequence for siRNAs using cultured MCs. Three different TGF-b specific siRNAs (siTGFA, siTGFB, and siTGFC) were synthesized. At 12 h after transfection of siTGFA, siTGFB, siTGFC or siSCR, at a final concentration of 20 nM, into subconfluent rat MCs using Lipofectamine 2000, serum-free medium was replaced with complete growth medium containing 20% FCS to stimulate TGF-b1 expression. After incubating further for 48 h, the effect of the siRNAs was assessed by Northern blot analysis.
As siTGFB appeared to be the most effective, this siRNA was further used in in vivo studies. At 24 h after induction of anti-Thy-1 nephritis, 50 mg of siTGFB or siSCR was transfected into rat glomeruli (n ¼ 6 in each group). TGF-b1 expression in the glomeruli was monitored by Northern blot analysis, Western blot analysis and immunohistochemistry 4 days after transfection.
Northern blot analysis
We examined the effect of siRNA on TGF-b1 mRNA expression in vitro and in vivo by Northern blot analysis. For in vitro studies, transfected rat MCs were rinsed twice with ice-cold PBS and scraped with 1 ml of Trizol reagent (Invitrogen). For in vivo studies, isolated glomeruli were homogenized with Polytron homogenizer (Kinematica, Switzerland) in Trizol reagent 4 days after siRNA transfection. In both studies, total RNA was extracted according to the manufacturer's protocol. TGFb1 and GAPDH cDNA were labeled with [a-32 P]dCTP (3000 Ci/mmol; Amersham Biosciences) by the random priming method (Rediprime II, Amersham Biosciences) and hybridization was carried out as described previously. 21 Autoradiographs were obtained and the density of each band was quantified using the laser densitometry (Scanning Imager; Molecular Dynamics, Sunnyvale, CA, USA). These experiments were repeated three times and the density of each band relative to that of GAPDH was calculated.
Western blot analysis
To study the effect of siRNA on glomerular TGF-b1 protein expression, Western blot analysis was performed. Collected glomeruli were homogenized in 1 ml of lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet-P40, 10% glycerol, 1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin and 0.5 mM sodium orthovanadate by tissue grinders (Iwaki, Tokyo, Japan) at 41C. The soluble lysates were mixed 1:2 with 3 Â Laemmli buffer and heated for 10 min at 951C. Lysates (20 mg) were loaded per lane, resolved by 15% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Hybond-P PVDF Membrane, Amersham Biosciences). Membranes were blocked with 5% bovine serum albumin in Tris-buffered saline (TBS)-Tween 20 (20 mM Tris-HCl (pH 7.5), 137 mM NaCl, 0.1% Tween 20 (vol/vol)) for 30 min at room temperature and Exploring RNAi for renal disease Y Takabatake et al then immunoblotted with polyclonal antibodies against TGF-b1 (Anti-TGFb1 pAb, 1:1000, Promega) in blocking buffer for 1 h at room temperature. The primary antibodies were detected using horseradish peroxidaseconjugated goat anti-rabbit IgG and visualized with SuperSignal West Pico Chemiluminescent Substrate (PIERCE, Rockford, IL, USA) according to the manufacturer's directions. The blots were exposed to X-ray film (Hyperfilm, Amersham Biosciences).
Morphological and immunohistochemical studies
Nephritic kidneys treated with siTGFB or siSCR were fixed in 4% PFA and paraffin-embedded. Contralateral nephritic kidneys were used as disease controls. For renal morphological studies, 4 mm sections were stained with the periodic acid-Schiff (PAS) reagent. Immunohistochemical stains for TGF-b1 and SMaA were performed using a streptavidin biotin-staining method (Vector ABC kit; Vector Laboratories). For TGF-b1 staining, sections were autoclaved in 0.01 M citrate buffer (pH 6.0) for 10 min at 1211C to retrieve the antigen. Rabbit antihuman TGF-b1 polyclonal antibody (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), which crossreacts with rat tissue, and mouse IgG anti-SMaA monoclonal antibody (Immunotech, Marseilles, France) were used.
Pathological changes in anti-Thy-1 nephritis model are heterogeneous among different glomeruli. Histological improvement of the disease manifestations was quantitatively estimated. For each samples, approximately 30 cortical glomerular cross sections containing vascular pole were evaluated in a blind fashion. Glomerular expression of TGF-b1 was graded semiquantitatively according to the score described elsewhere. 22 It ranged from 0 to 4; 0 ¼ glomerulus without any positive staining, 1 ¼ glomerulus with up to 25% positive staining, 2 ¼ glomerulus with 26-50% positive staining, 3 ¼ glomerulus with 51-75% positive staining, 4 ¼ glomerulus with 76-100% positive staining. Glomerular expression of SMaA was evaluated by computerized image analysis using Mac SCOPE program. In brief, selected glomeruli from each sample were photographed and positive areas were highlighted on the captured images. The area of positive staining relative to each glomerular area was automatically calculated as a percentage with determined threshold settings.
siRNA expression vectors
Oligodeoxynucleotides (64 nt) encoding hairpin siRNAs (shRNAs) targeting TGF-b1 (sequence B) were synthesized by Bex, annealed and ligated into BamHI and HindIII site of pSilencer 2.0-U6 siRNA expression vector, featuring human U6 RNA pol III promoter (Ambion, Inc., Austin, TX, USA) (pSU6TGFB). pSilencer containing scrambled sequences (pSU6SCR) was used as a negative control.
First, Northern blot analysis was performed to identify the transcripts of pSU6TGFB in vitro and in vivo. Total RNA was isolated from rat MCs and glomeruli transfected by pSU6TGFB. In total, 20 mg of total RNA was separated by electrophoresis on 15% (wt/vol) polyacrylamide-8 M urea gel and transferred onto a nylon membrane (Hybond-N+). Sense (5 0 -GTCAACTGTGGAG CAACAC-3 0 ) or antisense (5 0 -GTGTTGCTCCACAGTT GAC-3 0 ) oligodeoxynucleotide (19nt) was labeled by the 5 0 -end labeling method using [g-32 P] ATP (3000 Ci/ mmol; Amersham Biosciences) and T4 polynucleotide kinase (New England Biolabs, Inc., Beverley, MA, USA). The blots were hybridized with g-P 32 -labeled sense or antisense probe at 371C overnight. They were washed in 2 Â SSC and 0.1% SDS twice for 15 min at room temperature, twice for 15 min at 371C and subjected to autoradiography. Synthetic siTGFB (0.2 ng) was used as size-marker.
We then examined whether shRNA could inhibit TGFb expression in vitro and in vivo. We transfected 10 mg of pSU6TGFB into cultured MCs in 6 cm dishes or 200 mg of pSU6TGFB into nephritic kidneys (n ¼ 6). Next, we assessed the effect of shRNA by Northern blot analysis and Western blot analysis.
Statistical analyses
All values are expressed as means7s.d. Statistical significance was evaluated using the one-way analysis of variance (ANOVA). A P-value of o0.05 was considered significant.
